hrp0086p2-p643 | Growth P2 | ESPE2016
, Rohrer Tilman R
, Pournara Effie
, Pedersen Birgitte Tonnes
, Blankenstein Oliver
Background: NordiNet® IOS (NCT00960128), a non-interventional study, collects long-term effectiveness and safety data of GH (Norditropin®, Novo Nordisk) treatment in everyday clinical practice.Objective and hypotheses: Identify paediatric patients more likely to experience a second adverse event (AE).Method: Based on diagnosis at GH treatment start and associated risk for mortality, patients were cla...